RxDoctor Payments Data

Rosanne Harnois

Nurse Practitioner · Raleigh, NCNPI 1225492788

Payments from drug & device makers

$1,038in general payments, 2019–2025

Across 38 payments — averaging $27.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fresenius USA Marketing, Inc.$285
  • AstraZeneca$278
  • Bayer$120
  • Nxstage Medical, Inc.$85
  • Amgen$73
  • Akebia Therapeutics Inc$56
  • plus $141 from 6 others

What the payments were for

  • Food & beverage$1,038100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,038 in reported general payments places this provider in the 75th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$17,150
Medicare patients
58
Services billed
110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide85$233,051
AuryxiaFerric Citrate45$92,054
XphozahTenapanor Hcl11$57,181
Lanthanum Carbonate53$34,549
Sevelamer Carbonate127$23,558
VeltassaPatiromer Calcium Sorbitex17$13,644
Clonidine13$2,582
Midodrine Hcl53$888
Carvedilol57$478
Hydralazine Hcl46$385
Lidocaine-PrilocaineLidocaine/Prilocaine25$374
Amlodipine Besylate57$225
Omeprazole11$219
Gabapentin28$204
Lisinopril19$203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$285$233,05185 claims
Akebia Therapeutics IncAuryxia$56$92,05445 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →